bumetanide(redirected from Bumetanide Injection)
Also found in: Dictionary.
Pharmacologic class: Loop diuretic
Therapeutic class: Antihypertensive
Pregnancy risk category C
FDA Box Warning
• Drug is a potent diuretic; excessive amounts may cause profound diuresis with fluid and electrolyte depletion. Give only under careful medical supervision; adjust dosage and dosing schedule to patient's needs.
Inhibits reabsorption of sodium and chloride in distal renal tubules and ascending limb of loop of Henle; increases renal excretion of water, sodium, chloride, magnesium, hydrogen, and calcium. Also reduces increased fluid volume caused by renal vasodilation.
Injection: 0.25 mg/ml
Tablets: 0.5 mg, 1 mg, 2 mg
⊘Indications and dosages
➣ Edema caused by heart failure or hepatic or renal disease; adult nocturia
Adults: 0.5 to 2 mg/day P.O. as a single dose; up to two additional doses may be given q 4 to 5 hours (up to 10 mg/day). Or 0.5 to 1 mg I.V. or I.M., repeated q 2 to 3 hours as needed, up to 10 mg/day.
Adults: 0.5 mg/day P.O. Maximum dosage is 5 mg/day.
• Renal impairment
• Elderly patients
• Drug-related edema
• Hypersensitivity to drug or sulfonamides
• Uncorrected electrolyte imbalances
• Hepatic coma
• Anuria and oliguria
Use cautiously in:
• severe hepatic disease, electrolyte depletion, diabetes mellitus, worsening azotemia
• elderly patients
• pregnant or breastfeeding patients
• children younger than age 18.
• Know that oral or I.V. route is preferred, because I.M. administration may cause pain at injection site.
• Be aware that drug may be given alone or with other antihypertensives.
• Dilute with dextrose 5% in water, normal saline solution, or lactated Ringer's injection.
• Give I.V. dose slowly over 2 minutes.
• Give P.O. form with food or milk.
CNS: dizziness, headache, insomnia, nervousness, vertigo, weakness, paresthesia, confusion, fatigue, hand-flapping tremor, encephalopathy
CV: hypotension, ECG changes, chest pain, thrombophlebitis, arrhythmias
EENT: blurred vision, nystagmus, hearing loss, tinnitus
GI: nausea, vomiting, diarrhea, constipation, dyspepsia, gastric irritation, dry mouth, anorexia, acute pancreatitis
GU: polyuria, nocturia, glycosuria, premature ejaculation, difficulty maintaining erection, oliguria, renal failure
Metabolic: dehydration, hyperglycemia, hyperuricemia, hypokalemia, hypomagnesemia, hypochloremic alkalosis
Musculoskeletal: arthralgia; muscle cramps, aching, or tenderness
Skin: photosensitivity, hives, rash, pruritus, urticaria, diaphoresis
Other: pain, nipple tenderness
Drug-drug.Aminoglycosides, cisplatin: increased risk of ototoxicity
Amphotericin B, corticosteroids, mezlocillin, other diuretics, piperacillin, stimulant laxatives: additive hypokalemia
Anticoagulants, thrombolytics: increased bumetanide effects
Antihypertensives, nitrates: additive hypotension
Cardiac glycosides: increased risk of digoxin toxicity
Lithium: decreased lithium excretion, possible lithium toxicity
Neuromuscular blockers: prolonged neuromuscular blockade
Nonsteroidal anti-inflammatory drugs, probenecid: inhibition of diuretic response
Drug-diagnostic tests.Blood urea nitrogen (BUN), cholesterol, creatinine, glucose, nitrogenous compounds: increased levels
Calcium, magnesium, platelets, potassium, sodium: decreased levels
Drug-herbs.Dandelion: interference with diuretic activity
Ginseng: resistance to diuresis
Licorice: rapid potassium loss
Drug-behaviors.Acute alcohol ingestion: additive hypotension
• Weigh patient at start of therapy, and monitor weight throughout therapy.
• Monitor blood pressure regularly.
• Monitor serum electrolyte, uric acid, glucose, and BUN levels.
• Monitor elderly patients for extreme blood pressure changes, orthostatic hypotension, and dehydration.
• Advise patient to take drug in morning to prevent nocturia, and to take second dose (if required) in late afternoon.
• Instruct patient to move slowly when sitting up or standing, to avoid dizziness or light-headedness from sudden blood pressure drop.
• Caution patient to avoid alcohol because of increased risk of hypotension.
• Advise patient to eat foods high in potassium. Provide other dietary counseling as appropriate to help prevent or minimize electrolyte imbalances.
• Instruct patient to weigh himself often to help detect fluid retention.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.
bumetanide/bu·met·a·nide/ (bu-met´ah-nīd) a loop diuretic used in the treatment of edema, including that associated with congestive heart failure or hepatic or renal disease, and hypertension.
bumetanideA potent loop diuretic with a rapid onset but short duration of action, which is used for patients with congestive heart failure who respond poorly to furosemide.
Hypotension (especially orthostatic), drowsiness, headache.
bumetanideBumex® Cardiology A loop diuretic with a rapid onset but short duration of action indicated for Pts with HTN and CHF Contraindications Not indicated due to hypovolemia and fetal hypoxia. See Diuretic, Loop diuretic.
bumetanideA quick-acting DIURETIC drug used to relieve the fluid retention (OEDEMA) occurring in HEART FAILURE, kidney disease such as the NEPHROTIC SYNDROME and liver CIRRHOSIS. A brand name is Burinex.
drug class: loop diuretic;
action: acts on the loop of Henle to decrease reabsorption of chloride and sodium with resultant diuresis;
uses: treatment of edema in chronic heart disease, renal disease, pulmonary edema, ascites, and hypertension.